Merck Launches FosaMax Plus In China; More Launches For Diabetes And Cardiovascular Drugs Expected
This article was originally published in PharmAsia News
Following Eli Lilly’s launch of Forteo in China last November, Merck is launching FosaMax Plus, a vitamin D compounded version of its osteoporosis blockbuster FosaMax.
You may also be interested in...
With three large outcomes studies to read out interim or final results, 2012 is likely to be a pivotal year for Merck’s R&D, even as it rebalances its traditionally first-in-class emphasis to a hybrid model that also embraces best in class.
Merck Emerging Markets President Kevin Ali On The Branded Generics Business: An Interview With PharmAsia News (Part 1 of 2)
When Merck & Co. Inc. Emerging Markets President Kevin Ali speaks of innovation, it is emblematic of Merck's deep-rooted focus on new drug discovery, but the veteran executive now sees opportunities in the differentiated, branded generics segment. On a recent visit to India, Ali spoke to PharmAsia News' India Bureau about incrementally innovative drugs, access to affordable medicines and also Merck's plans in the BRIC-MT nations.